Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2

Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2

Blog Article

The successive emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has presented a major challenge in the management of the coronavirus disease (COVID-19) pandemic.There are growing concerns regarding the emerging variants escaping vaccines or therapeutic neutralizing antibodies.In this study, we conducted an epidemiological survey to identify SARS-CoV-2 variants that are sporadically Kids hooded towel proliferating in vaccine-advanced countries.

Subsequently, we created HiBiT-tagged virus-like particles displaying spike proteins derived from the variants to analyze the neutralizing efficacy of the BNT162b2 mRNA vaccine and several therapeutic antibodies.We found that the Mu variant and a derivative of the Delta strain with E484K and N501Y mutations significantly evaded vaccine-elicited neutralizing antibodies.This trend was also observed in the Beta and Gamma variants, although they are currently not prevalent.

Although 95.2% of the vaccinees exhibited prominent neutralizing activity against the prototype strain, only 73.8 and 78.

6% of the vaccinees exhibited neutralizing activity against the Mu and the Delta derivative variants, respectively.A long-term analysis showed that 88.8% of the vaccinees initially exhibited strong neutralizing activity against the currently circulating Delta strain; Sheets the number decreased to 31.

6% for the individuals at 6 months after vaccination.Notably, these variants were shown to be resistant to several therapeutic antibodies.Our findings demonstrate the differential neutralization efficacy of the COVID-19 vaccine and monoclonal antibodies against circulating variants, suggesting the need for pandemic alerts and booster vaccinations against the currently prevalent variants.